摘要
胃肠间质瘤（gastrointestinalstromaltumor，GIST）是最常见的胃肠道间叶源性肿瘤。经过近十余年的发展。GIST的治疗形成了以外科手术联合靶向药物的治疗模式。伊马替尼（imatinibmesylate，IM）作为GIST患者术后辅助治疗的一线药物，其应用显著减少了GIST患者的术后复发转移，延长了患者生存。对大多数高危风险GIST患者来说，目前SSGXVⅢ／AIO研究推荐伊马替尼术后辅助治疗至少应用3年。然而最佳的辅助治疗持续时间和随访方案尚未明确，仍处于边治疗边总结中，也期待能提出一指导个体化治疗的评估标准。
Gastrointestinal stromal tumor （GIST） represents the most common mesenchymal tumor of the gastrointestinal tract. With decades of development, surgical excision combined with molecular targeted agents is becoming the mode for the GIST treatment. Imatinib mesylate （IM） is the first-line therapy medicine for GIST adjuvant treatment, and it significantly reduces recurrence or metastasis and increases survival. According to the recently results of SSGXV Ⅲ/AIO study, imatinib adjuvant therapy should be administered for at least 3 years for the GIST patients with a high estimated risk of recurrence and metastasis after surgery. Nevertheless, theoptimal duration of the adjuvant therapy or the follow-up policy remains unclear, and we look forward to standard assessment criteria for individualized treatment.
出处
《中华胃肠外科杂志》
CAS
CSCD
2013年第3期212-215,共4页
Chinese Journal of Gastrointestinal Surgery
关键词
胃肠间质瘤
辅助治疗
伊马替尼
生存期
Gastrointestinal stromal tumors
Adjuvanttherapy
Imatinib mesylate
Life cycle
